Cantor Fitzgerald downgraded Alector (ALEC) to Neutral from Overweight without a price target after the company’s INFRONT-3 trial of latozinemab failed to meet its primary endpoint with no directly positive benefit. Alector’s other programs are too early to value, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC: